印度社区covid - 19疫苗接种后免疫不良事件及其与血型的关系:一项横断面研究

N. Pandit, Nilesh Patel
{"title":"印度社区covid - 19疫苗接种后免疫不良事件及其与血型的关系:一项横断面研究","authors":"N. Pandit, Nilesh Patel","doi":"10.4103/jihs.jihs_29_21","DOIUrl":null,"url":null,"abstract":"Introduction: In middle of the 3rd wave, COVID19 is now gradually making agent host environment balance at the world level. COVID19 vaccine is also available for the prevention of diseases. The two vaccines which are available in India till July 2021, they are COVISHIELD and Covaxin. There are various news heard about the relation of the ABO blood group and COVID19 disease. However, no study has tried to the relation of various blood groups and adverse events following immunization (AEFI). Methods: This was a community-based cross-sectional study. It was conducted online mode with the use of Google Forms. Study participants were Indian citizens and who took either Covishield or Covaxin as COVID19 vaccination. The pretested form was used, which consisted of various information regarding blood group of individual, vaccine, type of vaccine, doses of vaccine, side effects postvaccination, what is/are side effects and other information like do you have disease COVID19. Results: A total of 893 participated in the study, but out of them, 731 participants took vaccine either one or two doses. Most of the participants, 597 (87%), were from urban areas. The postCOVID19 vaccine AEFI prevalence was 69.7%. The association between ABO and Rh blood group and AEFI was not statistically significant. However, Covaxin has lesser side effects compared to COVISHIELD. Even a small group of COVID19 disease also had no association with ABO or Rh blood group. Conclusion: The side effects following the COVID19 vaccine are quite common. Majority were mild AEFI. There is no statistical association with blood group and postCOVID19 AEFI.","PeriodicalId":30637,"journal":{"name":"International Journal of Integrated Health Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Adverse event following immunization and relation with blood group following COVID19 Vaccination among Indian community: A cross-sectional study\",\"authors\":\"N. Pandit, Nilesh Patel\",\"doi\":\"10.4103/jihs.jihs_29_21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: In middle of the 3rd wave, COVID19 is now gradually making agent host environment balance at the world level. COVID19 vaccine is also available for the prevention of diseases. The two vaccines which are available in India till July 2021, they are COVISHIELD and Covaxin. There are various news heard about the relation of the ABO blood group and COVID19 disease. However, no study has tried to the relation of various blood groups and adverse events following immunization (AEFI). Methods: This was a community-based cross-sectional study. It was conducted online mode with the use of Google Forms. Study participants were Indian citizens and who took either Covishield or Covaxin as COVID19 vaccination. The pretested form was used, which consisted of various information regarding blood group of individual, vaccine, type of vaccine, doses of vaccine, side effects postvaccination, what is/are side effects and other information like do you have disease COVID19. Results: A total of 893 participated in the study, but out of them, 731 participants took vaccine either one or two doses. Most of the participants, 597 (87%), were from urban areas. The postCOVID19 vaccine AEFI prevalence was 69.7%. The association between ABO and Rh blood group and AEFI was not statistically significant. However, Covaxin has lesser side effects compared to COVISHIELD. Even a small group of COVID19 disease also had no association with ABO or Rh blood group. Conclusion: The side effects following the COVID19 vaccine are quite common. Majority were mild AEFI. There is no statistical association with blood group and postCOVID19 AEFI.\",\"PeriodicalId\":30637,\"journal\":{\"name\":\"International Journal of Integrated Health Sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Integrated Health Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jihs.jihs_29_21\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Integrated Health Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jihs.jihs_29_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

在第三波疫情中期,covid - 19正在逐步使全球范围内的代理主机环境趋于平衡。covid - 19疫苗也可用于预防疾病。到2021年7月,印度有两种疫苗可供使用,它们是COVISHIELD和Covaxin。关于ABO血型与covid - 19疾病的关系,有各种各样的新闻。然而,目前还没有研究试图探讨不同血型与免疫接种后不良事件(AEFI)的关系。方法:这是一项以社区为基础的横断面研究。调查采用在线模式,使用Google表单。研究参与者是印度公民,他们接种了Covishield或Covaxin作为covid - 19疫苗。使用了预先测试的表格,其中包括个人血型、疫苗、疫苗类型、疫苗剂量、疫苗接种后的副作用、副作用是什么以及其他信息,如您是否患有covid - 19疾病。结果:共有893人参加了这项研究,但其中731人接种了一剂或两剂疫苗。大多数参与者,597人(87%)来自城市地区。新型冠状病毒疫苗后AEFI患病率为69.7%。ABO血型和Rh血型与AEFI的相关性无统计学意义。然而,与COVISHIELD相比,Covaxin的副作用较小。即使是一小部分covid - 19疾病也与ABO或Rh血型无关。结论:新型冠状病毒疫苗接种后的副作用相当普遍。大多数为轻度AEFI。与血型和冠状病毒后急性呼吸损伤无统计学关联。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Adverse event following immunization and relation with blood group following COVID19 Vaccination among Indian community: A cross-sectional study
Introduction: In middle of the 3rd wave, COVID19 is now gradually making agent host environment balance at the world level. COVID19 vaccine is also available for the prevention of diseases. The two vaccines which are available in India till July 2021, they are COVISHIELD and Covaxin. There are various news heard about the relation of the ABO blood group and COVID19 disease. However, no study has tried to the relation of various blood groups and adverse events following immunization (AEFI). Methods: This was a community-based cross-sectional study. It was conducted online mode with the use of Google Forms. Study participants were Indian citizens and who took either Covishield or Covaxin as COVID19 vaccination. The pretested form was used, which consisted of various information regarding blood group of individual, vaccine, type of vaccine, doses of vaccine, side effects postvaccination, what is/are side effects and other information like do you have disease COVID19. Results: A total of 893 participated in the study, but out of them, 731 participants took vaccine either one or two doses. Most of the participants, 597 (87%), were from urban areas. The postCOVID19 vaccine AEFI prevalence was 69.7%. The association between ABO and Rh blood group and AEFI was not statistically significant. However, Covaxin has lesser side effects compared to COVISHIELD. Even a small group of COVID19 disease also had no association with ABO or Rh blood group. Conclusion: The side effects following the COVID19 vaccine are quite common. Majority were mild AEFI. There is no statistical association with blood group and postCOVID19 AEFI.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
9
审稿时长
8 weeks
期刊最新文献
Examining the Influence of Joint Commission International (JCI) Accreditation Surveys on Medication Safety Practices: A Cross-Sectional Study from Mediclinic Welcare Hospital in Dubai, UAE The Gift of Life Fever, Significant Pyuria and A Positive Urine Culture not Always A Urine Infection (UTI) Intention to Consume Alcohol among Dayak Adolescents in Sarawak: An Application of Theory of Planned Behavior Paradoxical Hemiparesis from Cerebellopontine Angle Tumor: A Case Report
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1